What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

The study aims to evaluate the safety and efficacy of TGD001 for thrombolysis in iTTP and acute ischemic stroke.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial demonstrates TGD001's safety and thrombolytic potential in acute thrombotic conditions, implying impactful clinical outcomes.

The study aims to evaluate the safety and efficacy of TGD001 for thrombolysis in iTTP and acute ischemic stroke.
Randomized, double-blind, placebo-controlled Phase 1 trial
34 healthy adult males across four dose cohorts
Single intravenous administration of TGD001
Assessment of safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers
TGD001 was well tolerated with 16 reported adverse events, predominantly mild and transient
Pharmacokinetic profile showed dose-proportionality and variability in half-life
Key pharmacodynamic biomarkers indicated dose-dependent trends

Paul T. Brinkkoetter (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1 trial demonstrates TGD001's safety and thrombolytic potential in acute thrombotic conditions, implying impactful clinical outcomes.